Click for best price
PEGylated Drugs Market Size, Share 2023
| Market size in 2022 |
US$ 7206.3 million
|
Forecast Market size by 2029 |
US$ 8691.5 million
|
| Growth Rate |
CAGR of 2.7% |
Number of Pages |
106 Pages |
The global PEGylated Drugs market was valued at US$ 7206.3 million in 2022 and is projected to reach US$ 8691.5 million by 2029, at a CAGR of 2.7% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report aims to provide a comprehensive presentation of the global market for PEGylated Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PEGylated Drugs. This report contains market size and forecasts of PEGylated Drugs in global, including the following market information:
Global PEGylated Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Macromolecular Drugs Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of PEGylated Drugs include AstraZeneca, Bayer Healthcare, Biogen, BioMarin Pharmaceutical Inc, Coherus BioSciences, Enzon, Horizon Therapeutics, Leadiant Biosciences, Inc. and Merck, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the PEGylated Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global PEGylated Drugs Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global PEGylated Drugs Market Segment Percentages, by Type, 2022 (%)
- Macromolecular Drugs
- Small Molecular Drugs
- Nanoparticles
Global PEGylated Drugs Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global PEGylated Drugs Market Segment Percentages, by Application, 2022 (%)
- Cancer
- Hepatitis C
- Leukemia
- Severe Combined Immunodeficiency Disease
- Rheumatoid Arthritis
- Crohn Disease
- Others
Global PEGylated Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global PEGylated Drugs Market Segment Percentages, By Region and Country, 2022 (%)
- North America (United States, Canada, Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies PEGylated Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies PEGylated Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- AstraZeneca
- Bayer Healthcare
- Biogen
- BioMarin Pharmaceutical Inc
- Coherus BioSciences
- Enzon
- Horizon Therapeutics
- Leadiant Biosciences, Inc.
- Merck
- Mylan
- Novo Nordisk
- Pfizer
- Roche
- Sandoz
- Servier Pharmaceuticals LLC
- Takeda Pharmaceutical Company Limited
Outline of Major Chapters:
Chapter 1: Introduces the definition of PEGylated Drugs, market overview.
Chapter 2: Global PEGylated Drugs market size in revenue.
Chapter 3: Detailed analysis of PEGylated Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of PEGylated Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
PEGylated Drugs Market, Global Outlook and Forecast 2023-2032 |
| Market size in 2022 |
US$ 7206.3 million
|
| Forecast Market size by 2029 |
US$ 8691.5 million
|
| Growth Rate |
CAGR of 2.7% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
106 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 PEGylated Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global PEGylated Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global PEGylated Drugs Overall Market Size
2.1 Global PEGylated Drugs Market Size: 2022 VS 2032
2.2 Global PEGylated Drugs Market Size, Prospects & Forecasts: 2018-2032
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top PEGylated Drugs Players in Global Market
3.2 Top Global PEGylated Drugs Companies Ranked by Revenue
3.3 Global PEGylated Drugs Revenue by Companies
3.4 Top 3 and Top 5 PEGylated Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies PEGylated Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 PEGylated Drugs Players in Global Market
3.6.1 List of Global Tier 1 PEGylated Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 PEGylated Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global PEGylated Drugs Market Size Markets, 2022 & 2032
4.1.2 Macromolecular Drugs
4.1.3 Small Molecular Drugs
4.1.4 Nanoparticles
4.2 By Type - Global PEGylated Drugs Revenue & Forecasts
4.2.1 By Type - Global PEGylated Drugs Revenue, 2018-2023
4.2.2 By Type - Global PEGylated Drugs Revenue, 2024-2032
4.2.3 By Type - Global PEGylated Drugs Revenue Market Share, 2018-2032
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global PEGylated Drugs Market Size, 2022 & 2032
5.1.2 Cancer
5.1.3 Hepatitis C
5.1.4 Leukemia
5.1.5 Severe Combined Immunodeficiency Disease
5.1.6 Rheumatoid Arthritis
5.1.7 Crohn Disease
5.1.8 Others
5.2 By Application - Global PEGylated Drugs Revenue & Forecasts
5.2.1 By Application - Global PEGylated Drugs Revenue, 2018-2023
5.2.2 By Application - Global PEGylated Drugs Revenue, 2024-2032
5.2.3 By Application - Global PEGylated Drugs Revenue Market Share, 2018-2032
6 Sights by Region
6.1 By Region - Global PEGylated Drugs Market Size, 2022 & 2032
6.2 By Region - Global PEGylated Drugs Revenue & Forecasts
6.2.1 By Region - Global PEGylated Drugs Revenue, 2018-2023
6.2.2 By Region - Global PEGylated Drugs Revenue, 2024-2032
6.2.3 By Region - Global PEGylated Drugs Revenue Market Share, 2018-2032
6.3 North America
6.3.1 By Country - North America PEGylated Drugs Revenue, 2018-2032
6.3.2 US PEGylated Drugs Market Size, 2018-2032
6.3.3 Canada PEGylated Drugs Market Size, 2018-2032
6.3.4 Mexico PEGylated Drugs Market Size, 2018-2032
6.4 Europe
6.4.1 By Country - Europe PEGylated Drugs Revenue, 2018-2032
6.4.2 Germany PEGylated Drugs Market Size, 2018-2032
6.4.3 France PEGylated Drugs Market Size, 2018-2032
6.4.4 U.K. PEGylated Drugs Market Size, 2018-2032
6.4.5 Italy PEGylated Drugs Market Size, 2018-2032
6.4.6 Russia PEGylated Drugs Market Size, 2018-2032
6.4.7 Nordic Countries PEGylated Drugs Market Size, 2018-2032
6.4.8 Benelux PEGylated Drugs Market Size, 2018-2032
6.5 Asia
6.5.1 By Region - Asia PEGylated Drugs Revenue, 2018-2032
6.5.2 China PEGylated Drugs Market Size, 2018-2032
6.5.3 Japan PEGylated Drugs Market Size, 2018-2032
6.5.4 South Korea PEGylated Drugs Market Size, 2018-2032
6.5.5 Southeast Asia PEGylated Drugs Market Size, 2018-2032
6.5.6 India PEGylated Drugs Market Size, 2018-2032
6.6 South America
6.6.1 By Country - South America PEGylated Drugs Revenue, 2018-2032
6.6.2 Brazil PEGylated Drugs Market Size, 2018-2032
6.6.3 Argentina PEGylated Drugs Market Size, 2018-2032
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa PEGylated Drugs Revenue, 2018-2032
6.7.2 Turkey PEGylated Drugs Market Size, 2018-2032
6.7.3 Israel PEGylated Drugs Market Size, 2018-2032
6.7.4 Saudi Arabia PEGylated Drugs Market Size, 2018-2032
6.7.5 UAE PEGylated Drugs Market Size, 2018-2032
7 PEGylated Drugs Companies Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Company Summary
7.1.2 AstraZeneca Business Overview
7.1.3 AstraZeneca PEGylated Drugs Major Product Offerings
7.1.4 AstraZeneca PEGylated Drugs Revenue in Global Market (2018-2023)
7.1.5 AstraZeneca Key News & Latest Developments
7.2 Bayer Healthcare
7.2.1 Bayer Healthcare Company Summary
7.2.2 Bayer Healthcare Business Overview
7.2.3 Bayer Healthcare PEGylated Drugs Major Product Offerings
7.2.4 Bayer Healthcare PEGylated Drugs Revenue in Global Market (2018-2023)
7.2.5 Bayer Healthcare Key News & Latest Developments
7.3 Biogen
7.3.1 Biogen Company Summary
7.3.2 Biogen Business Overview
7.3.3 Biogen PEGylated Drugs Major Product Offerings
7.3.4 Biogen PEGylated Drugs Revenue in Global Market (2018-2023)
7.3.5 Biogen Key News & Latest Developments
7.4 BioMarin Pharmaceutical Inc
7.4.1 BioMarin Pharmaceutical Inc Company Summary
7.4.2 BioMarin Pharmaceutical Inc Business Overview
7.4.3 BioMarin Pharmaceutical Inc PEGylated Drugs Major Product Offerings
7.4.4 BioMarin Pharmaceutical Inc PEGylated Drugs Revenue in Global Market (2018-2023)
7.4.5 BioMarin Pharmaceutical Inc Key News & Latest Developments
7.5 Coherus BioSciences
7.5.1 Coherus BioSciences Company Summary
7.5.2 Coherus BioSciences Business Overview
7.5.3 Coherus BioSciences PEGylated Drugs Major Product Offerings
7.5.4 Coherus BioSciences PEGylated Drugs Revenue in Global Market (2018-2023)
7.5.5 Coherus BioSciences Key News & Latest Developments
7.6 Enzon
7.6.1 Enzon Company Summary
7.6.2 Enzon Business Overview
7.6.3 Enzon PEGylated Drugs Major Product Offerings
7.6.4 Enzon PEGylated Drugs Revenue in Global Market (2018-2023)
7.6.5 Enzon Key News & Latest Developments
7.7 Horizon Therapeutics
7.7.1 Horizon Therapeutics Company Summary
7.7.2 Horizon Therapeutics Business Overview
7.7.3 Horizon Therapeutics PEGylated Drugs Major Product Offerings
7.7.4 Horizon Therapeutics PEGylated Drugs Revenue in Global Market (2018-2023)
7.7.5 Horizon Therapeutics Key News & Latest Developments
7.8 Leadiant Biosciences, Inc.
7.8.1 Leadiant Biosciences, Inc. Company Summary
7.8.2 Leadiant Biosciences, Inc. Business Overview
7.8.3 Leadiant Biosciences, Inc. PEGylated Drugs Major Product Offerings
7.8.4 Leadiant Biosciences, Inc. PEGylated Drugs Revenue in Global Market (2018-2023)
7.8.5 Leadiant Biosciences, Inc. Key News & Latest Developments
7.9 Merck
7.9.1 Merck Company Summary
7.9.2 Merck Business Overview
7.9.3 Merck PEGylated Drugs Major Product Offerings
7.9.4 Merck PEGylated Drugs Revenue in Global Market (2018-2023)
7.9.5 Merck Key News & Latest Developments
7.10 Mylan
7.10.1 Mylan Company Summary
7.10.2 Mylan Business Overview
7.10.3 Mylan PEGylated Drugs Major Product Offerings
7.10.4 Mylan PEGylated Drugs Revenue in Global Market (2018-2023)
7.10.5 Mylan Key News & Latest Developments
7.11 Novo Nordisk
7.11.1 Novo Nordisk Company Summary
7.11.2 Novo Nordisk Business Overview
7.11.3 Novo Nordisk PEGylated Drugs Major Product Offerings
7.11.4 Novo Nordisk PEGylated Drugs Revenue in Global Market (2018-2023)
7.11.5 Novo Nordisk Key News & Latest Developments
7.12 Pfizer
7.12.1 Pfizer Company Summary
7.12.2 Pfizer Business Overview
7.12.3 Pfizer PEGylated Drugs Major Product Offerings
7.12.4 Pfizer PEGylated Drugs Revenue in Global Market (2018-2023)
7.12.5 Pfizer Key News & Latest Developments
7.13 Roche
7.13.1 Roche Company Summary
7.13.2 Roche Business Overview
7.13.3 Roche PEGylated Drugs Major Product Offerings
7.13.4 Roche PEGylated Drugs Revenue in Global Market (2018-2023)
7.13.5 Roche Key News & Latest Developments
7.14 Sandoz
7.14.1 Sandoz Company Summary
7.14.2 Sandoz Business Overview
7.14.3 Sandoz PEGylated Drugs Major Product Offerings
7.14.4 Sandoz PEGylated Drugs Revenue in Global Market (2018-2023)
7.14.5 Sandoz Key News & Latest Developments
7.15 Servier Pharmaceuticals LLC
7.15.1 Servier Pharmaceuticals LLC Company Summary
7.15.2 Servier Pharmaceuticals LLC Business Overview
7.15.3 Servier Pharmaceuticals LLC PEGylated Drugs Major Product Offerings
7.15.4 Servier Pharmaceuticals LLC PEGylated Drugs Revenue in Global Market (2018-2023)
7.15.5 Servier Pharmaceuticals LLC Key News & Latest Developments
7.16 Takeda Pharmaceutical Company Limited
7.16.1 Takeda Pharmaceutical Company Limited Company Summary
7.16.2 Takeda Pharmaceutical Company Limited Business Overview
7.16.3 Takeda Pharmaceutical Company Limited PEGylated Drugs Major Product Offerings
7.16.4 Takeda Pharmaceutical Company Limited PEGylated Drugs Revenue in Global Market (2018-2023)
7.16.5 Takeda Pharmaceutical Company Limited Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. PEGylated Drugs Market Opportunities & Trends in Global Market
Table 2. PEGylated Drugs Market Drivers in Global Market
Table 3. PEGylated Drugs Market Restraints in Global Market
Table 4. Key Players of PEGylated Drugs in Global Market
Table 5. Top PEGylated Drugs Players in Global Market, Ranking by Revenue (2022)
Table 6. Global PEGylated Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global PEGylated Drugs Revenue Share by Companies, 2018-2023
Table 8. Global Companies PEGylated Drugs Product Type
Table 9. List of Global Tier 1 PEGylated Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 PEGylated Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global PEGylated Drugs Revenue, (US$, Mn), 2022 & 2032
Table 12. By Type - PEGylated Drugs Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - PEGylated Drugs Revenue in Global (US$, Mn), 2024-2032
Table 14. By Application ? Global PEGylated Drugs Revenue, (US$, Mn), 2022 & 2032
Table 15. By Application - PEGylated Drugs Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - PEGylated Drugs Revenue in Global (US$, Mn), 2024-2032
Table 17. By Region ? Global PEGylated Drugs Revenue, (US$, Mn), 2022 & 2032
Table 18. By Region - Global PEGylated Drugs Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global PEGylated Drugs Revenue (US$, Mn), 2024-2032
Table 20. By Country - North America PEGylated Drugs Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America PEGylated Drugs Revenue, (US$, Mn), 2024-2032
Table 22. By Country - Europe PEGylated Drugs Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe PEGylated Drugs Revenue, (US$, Mn), 2024-2032
Table 24. By Region - Asia PEGylated Drugs Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia PEGylated Drugs Revenue, (US$, Mn), 2024-2032
Table 26. By Country - South America PEGylated Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America PEGylated Drugs Revenue, (US$, Mn), 2024-2032
Table 28. By Country - Middle East & Africa PEGylated Drugs Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa PEGylated Drugs Revenue, (US$, Mn), 2024-2032
Table 30. AstraZeneca Company Summary
Table 31. AstraZeneca PEGylated Drugs Product Offerings
Table 32. AstraZeneca PEGylated Drugs Revenue (US$, Mn) & (2018-2023)
Table 33. AstraZeneca Key News & Latest Developments
Table 34. Bayer Healthcare Company Summary
Table 35. Bayer Healthcare PEGylated Drugs Product Offerings
Table 36. Bayer Healthcare PEGylated Drugs Revenue (US$, Mn) & (2018-2023)
Table 37. Bayer Healthcare Key News & Latest Developments
Table 38. Biogen Company Summary
Table 39. Biogen PEGylated Drugs Product Offerings
Table 40. Biogen PEGylated Drugs Revenue (US$, Mn) & (2018-2023)
Table 41. Biogen Key News & Latest Developments
Table 42. BioMarin Pharmaceutical Inc Company Summary
Table 43. BioMarin Pharmaceutical Inc PEGylated Drugs Product Offerings
Table 44. BioMarin Pharmaceutical Inc PEGylated Drugs Revenue (US$, Mn) & (2018-2023)
Table 45. BioMarin Pharmaceutical Inc Key News & Latest Developments
Table 46. Coherus BioSciences Company Summary
Table 47. Coherus BioSciences PEGylated Drugs Product Offerings
Table 48. Coherus BioSciences PEGylated Drugs Revenue (US$, Mn) & (2018-2023)
Table 49. Coherus BioSciences Key News & Latest Developments
Table 50. Enzon Company Summary
Table 51. Enzon PEGylated Drugs Product Offerings
Table 52. Enzon PEGylated Drugs Revenue (US$, Mn) & (2018-2023)
Table 53. Enzon Key News & Latest Developments
Table 54. Horizon Therapeutics Company Summary
Table 55. Horizon Therapeutics PEGylated Drugs Product Offerings
Table 56. Horizon Therapeutics PEGylated Drugs Revenue (US$, Mn) & (2018-2023)
Table 57. Horizon Therapeutics Key News & Latest Developments
Table 58. Leadiant Biosciences, Inc. Company Summary
Table 59. Leadiant Biosciences, Inc. PEGylated Drugs Product Offerings
Table 60. Leadiant Biosciences, Inc. PEGylated Drugs Revenue (US$, Mn) & (2018-2023)
Table 61. Leadiant Biosciences, Inc. Key News & Latest Developments
Table 62. Merck Company Summary
Table 63. Merck PEGylated Drugs Product Offerings
Table 64. Merck PEGylated Drugs Revenue (US$, Mn) & (2018-2023)
Table 65. Merck Key News & Latest Developments
Table 66. Mylan Company Summary
Table 67. Mylan PEGylated Drugs Product Offerings
Table 68. Mylan PEGylated Drugs Revenue (US$, Mn) & (2018-2023)
Table 69. Mylan Key News & Latest Developments
Table 70. Novo Nordisk Company Summary
Table 71. Novo Nordisk PEGylated Drugs Product Offerings
Table 72. Novo Nordisk PEGylated Drugs Revenue (US$, Mn) & (2018-2023)
Table 73. Novo Nordisk Key News & Latest Developments
Table 74. Pfizer Company Summary
Table 75. Pfizer PEGylated Drugs Product Offerings
Table 76. Pfizer PEGylated Drugs Revenue (US$, Mn) & (2018-2023)
Table 77. Pfizer Key News & Latest Developments
Table 78. Roche Company Summary
Table 79. Roche PEGylated Drugs Product Offerings
Table 80. Roche PEGylated Drugs Revenue (US$, Mn) & (2018-2023)
Table 81. Roche Key News & Latest Developments
Table 82. Sandoz Company Summary
Table 83. Sandoz PEGylated Drugs Product Offerings
Table 84. Sandoz PEGylated Drugs Revenue (US$, Mn) & (2018-2023)
Table 85. Sandoz Key News & Latest Developments
Table 86. Servier Pharmaceuticals LLC Company Summary
Table 87. Servier Pharmaceuticals LLC PEGylated Drugs Product Offerings
Table 88. Servier Pharmaceuticals LLC PEGylated Drugs Revenue (US$, Mn) & (2018-2023)
Table 89. Servier Pharmaceuticals LLC Key News & Latest Developments
Table 90. Takeda Pharmaceutical Company Limited Company Summary
Table 91. Takeda Pharmaceutical Company Limited PEGylated Drugs Product Offerings
Table 92. Takeda Pharmaceutical Company Limited PEGylated Drugs Revenue (US$, Mn) & (2018-2023)
Table 93. Takeda Pharmaceutical Company Limited Key News & Latest Developments
List of Figures
Figure 1. PEGylated Drugs Segment by Type in 2022
Figure 2. PEGylated Drugs Segment by Application in 2022
Figure 3. Global PEGylated Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global PEGylated Drugs Market Size: 2022 VS 2032 (US$, Mn)
Figure 6. Global PEGylated Drugs Revenue, 2018-2032 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by PEGylated Drugs Revenue in 2022
Figure 8. By Type - Global PEGylated Drugs Revenue Market Share, 2018-2032
Figure 9. By Application - Global PEGylated Drugs Revenue Market Share, 2018-2032
Figure 10. By Type - Global PEGylated Drugs Revenue, (US$, Mn), 2022 & 2032
Figure 11. By Type - Global PEGylated Drugs Revenue Market Share, 2018-2032
Figure 12. By Application - Global PEGylated Drugs Revenue, (US$, Mn), 2022 & 2032
Figure 13. By Application - Global PEGylated Drugs Revenue Market Share, 2018-2032
Figure 14. By Region - Global PEGylated Drugs Revenue Market Share, 2018-2032
Figure 15. By Country - North America PEGylated Drugs Revenue Market Share, 2018-2032
Figure 16. US PEGylated Drugs Revenue, (US$, Mn), 2018-2032
Figure 17. Canada PEGylated Drugs Revenue, (US$, Mn), 2018-2032
Figure 18. Mexico PEGylated Drugs Revenue, (US$, Mn), 2018-2032
Figure 19. By Country - Europe PEGylated Drugs Revenue Market Share, 2018-2032
Figure 20. Germany PEGylated Drugs Revenue, (US$, Mn), 2018-2032
Figure 21. France PEGylated Drugs Revenue, (US$, Mn), 2018-2032
Figure 22. U.K. PEGylated Drugs Revenue, (US$, Mn), 2018-2032
Figure 23. Italy PEGylated Drugs Revenue, (US$, Mn), 2018-2032
Figure 24. Russia PEGylated Drugs Revenue, (US$, Mn), 2018-2032
Figure 25. Nordic Countries PEGylated Drugs Revenue, (US$, Mn), 2018-2032
Figure 26. Benelux PEGylated Drugs Revenue, (US$, Mn), 2018-2032
Figure 27. By Region - Asia PEGylated Drugs Revenue Market Share, 2018-2032
Figure 28. China PEGylated Drugs Revenue, (US$, Mn), 2018-2032
Figure 29. Japan PEGylated Drugs Revenue, (US$, Mn), 2018-2032
Figure 30. South Korea PEGylated Drugs Revenue, (US$, Mn), 2018-2032
Figure 31. Southeast Asia PEGylated Drugs Revenue, (US$, Mn), 2018-2032
Figure 32. India PEGylated Drugs Revenue, (US$, Mn), 2018-2032
Figure 33. By Country - South America PEGylated Drugs Revenue Market Share, 2018-2032
Figure 34. Brazil PEGylated Drugs Revenue, (US$, Mn), 2018-2032
Figure 35. Argentina PEGylated Drugs Revenue, (US$, Mn), 2018-2032
Figure 36. By Country - Middle East & Africa PEGylated Drugs Revenue Market Share, 2018-2032
Figure 37. Turkey PEGylated Drugs Revenue, (US$, Mn), 2018-2032
Figure 38. Israel PEGylated Drugs Revenue, (US$, Mn), 2018-2032
Figure 39. Saudi Arabia PEGylated Drugs Revenue, (US$, Mn), 2018-2032
Figure 40. UAE PEGylated Drugs Revenue, (US$, Mn), 2018-2032
Figure 41. AstraZeneca PEGylated Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Bayer Healthcare PEGylated Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Biogen PEGylated Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. BioMarin Pharmaceutical Inc PEGylated Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Coherus BioSciences PEGylated Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Enzon PEGylated Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Horizon Therapeutics PEGylated Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Leadiant Biosciences, Inc. PEGylated Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Merck PEGylated Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Mylan PEGylated Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Novo Nordisk PEGylated Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Pfizer PEGylated Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Roche PEGylated Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Sandoz PEGylated Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Servier Pharmaceuticals LLC PEGylated Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Takeda Pharmaceutical Company Limited PEGylated Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
